Takeda Pharmaceutical Co ADR (NYSE:TAK) currently has a daily average trading volume of 1.91M but it saw 1674582 shares traded in last market. With a market cap of 47.65B USD, the company’s current market price of $15.03 came falling about -1.70 while comparing to the previous closing price of $15.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $15.37 and as low as $12.57. In the recent trading on the day, stock has struck highest price mark of $15.01 while lowest mark touched by it was $15.2.
Taking a look at 20-day trading activity of Takeda Pharmaceutical Co ADR (TAK) gives us an average price of $14.75, while its current price level is -2.21% below from 52-week high level whereas it is 19.52% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $14.80 while that of 200 days or SMA-200 reads an average of $14.10. A closer look into the stock’s movement over the week reveals that its volatility is standing at 1.08% during that period while stretching the period over a month that increases to 1.90%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.90 which implies that the stock is in neutral territory.
BofA Securities upgraded its recommendation for the stock as a “Buy” from “Neutral” on March 16, 2023 while assigning a price target of $20. Cowen also issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $21 and $24.
Over the week, TAK’s stock price is moving -0.53% down while it is 0.87% when we observe its performance for the past one month. Year-to-date it is 13.52% up and over the past year, the stock is showing an upside performance of 14.12%.
The company is expected to be releasing its next quarterly report on 2025-Jan-29, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0. In next quarter, company is expected to be making quarterly sales of $1.15T as analysts are expecting the sales for current fiscal year at $4.61T and seeing the company making $4.6T in sales next year. Moreover, analysts are in estimates of $1.07T for current-quarter revenue.
Currently, Takeda Pharmaceutical Co ADR’s total number of outstanding shares is 3.17B with 0.01% of that held by the insiders while 2.35% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 1.77% and return on equity (ROE) at 2.87%. It has a price to earnings ratio (P/E ratio) of 35.35 while having a 30.40 of forward P/E ratio. Stock’s beta reads 0.29. Stock has a price to book (P/B) ratio of 1.01 while price to sale or P/S ratio amounts to 1.58. Its return on asset (ROA) is 1.38% on average.
